SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced positive data from its pivotal clinical trial of the companys novel investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT. These preliminary data were recently provided to FDA as part of the companys ongoing interactions with the Agency on the narsoplimab Biologics License Application (BLA). All safety and efficacy endpoints including the composite primary endpoint and the secondary endpoints are agreed with FDA. The reported data support a strongly positive benefit-risk balance.
The primary efficacy endpoint in this single-arm open-label trial of HSCT-TMA patients is the proportion of patients who achieve a highly rigorous set of response criteria that requires both improvement in HSCT-TMA laboratory markers and improvement in clinical status (organ function and transfusions). Patients who did not fully meet these criteria were considered non-responders. The secondary endpoints include survival rates and change from baseline in HSCT-TMA laboratory markers. Consistent with the pre-specified statistical analysis plan for the trial, the primary and secondary endpoints are assessed for (1) all patients who received at least one dose of narsoplimab and (2) patients who received at least 4 weeks of narsoplimab dosing. Patients enrolled in this trial had a high expected mortality rate. In severe cases of HSCT-TMA, mortality can exceed 90 percent.
Primary Efficacy Endpoint:
The HSCT-TMA patient population enrolled in this trial had multiple high-risk features that portend a poor outcome. These include persistence of HSCT-TMA despite modification of immunosuppression (which was a criterion for entry into the trial), graft-versus-host disease, significant infections, non-infectious pulmonary complications and neurological findings. Patients in the trial had a high expected death rate, with 93 percent of them having multiple risk factors.
Patient enrollment in the pivotal trial has been completed. The details of the endpoints, including the response criteria agreed with FDA, and the number of patients in the trial remain confidential for competitive business reasons.
Last year the company reported data on 19 HSCT-TMA patients treated with narsoplimab on which FDA granted breakthrough therapy designation. The results reported today are even stronger. The response rate remains equally high at 56 percent, while the 100-day survival has improved from 53 percent to 65 percent.
The response rate in this high-risk population would be expected to be 10 to 15 percent with a 100-day survival rate of less than 20 percent. The response rate and 100-day survival achieved with narsoplimab in this trial demonstrate an unprecedented effect in this condition, said Rafael Duarte M.D., Ph.D., F.R.C.P., Associate Professor, Head of Hematology Department and Hematopoietic Transplantation Program, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain, and Secretary of the European Society for Blood and Marrow Transplantation. The other secondary endpoints are equally impressive. The data are consistent with my personal experience with narsoplimab. Patients with severe forms of HSCT-TMA have a dismal prognosis with no treatment currently available. I expect a treatment with this profile would be widely adopted for use in these patients and even lead to increased physician recognition of the disorder.
Omeros reported the initiation of its rolling BLA in October. Narsoplimab, also referred to as OMS721, is Omeros lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) and has breakthrough therapy designation from FDA for this indication.
The striking results seen in our pivotal trial are tremendously gratifying, said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. Our rolling BLA is underway the nonclinical sections have been submitted and the data from this trial form the efficacy basis of the application. We continue to compile the remaining sections of the BLA and look forward to continued partnership with regulators to make narsoplimab widely available for the treatment of this devastating condition.
Data from this pivotal trial will also support the narsoplimab marketing authorization application for HSCT-TMA in Europe. The data are planned for publication and for presentation at international congresses in the first part of 2020.
In addition to breakthrough therapy designation from FDA, narsoplimab has orphan drug designation in both the U.S. and Europe for HSCT-TMA. Narsoplimab also has been awarded breakthrough therapy designation for immunoglobulin A nephropathy (IgAN), and Omeros has Phase 3 programs for narsoplimab ongoing in IgAN and in atypical hemolytic uremic syndrome (aHUS).
Conference Call and Webcast Details
Omeros management will host a webcast and conference call to present data from its pivotal trial of narsoplimab in HSCT-TMA. The call will be held today at 8:30 a.m. Eastern Time; 5:30 a.m. Pacific Time. To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 3774209. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 3774209.
To access the live or subsequently archived webcast and presentation materials on the internet, go to the companys website at http://www.omeros.com and select Events under the Investors section of the website. To access the live webcast, please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse. In addition, the company has a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a significant and often lethal complication of stem cell transplants. This condition is a systemic, multifactorial disorder caused by endothelial cell damage induced by conditioning regimens, immunosuppressant therapies, infection, GvHD, and other factors associated with stem cell transplantation. Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of HSCT-TMA. The condition occurs in both autologous and allogeneic transplants but is more common in the allogeneic population. In the United States and Europe, approximately 25,000 to 30,000 allogeneic transplants are performed annually. Recent reports in both adult and pediatric allogeneic stem cell transplant populations have found an HSCT-TMA incidence of approximately 40 percent, and high-risk features may be present in up to 80 percent of these patients. In severe cases of HSCT-TMA, mortality can exceed 90 percent and, even in those who survive, long-term renal sequalae are common. There is no approved therapy or standard of care for HSCT-TMA.
Narsoplimab, also known as OMS721, is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.
Phase 3 clinical programs are in progress for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), in immunoglobulin A (IgA) nephropathy, and in atypical hemolytic uremic syndrome (aHUS). The FDA has granted narsoplimab breakthrough therapy designations for HSCT-TMA and for IgA nephropathy; orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies, for the treatment of HSCT-TMA and for the treatment of IgA nephropathy; and fast track designation for the treatment of patients with aHUS. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in HSCT and for treatment of primary IgA nephropathy.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the safe harbor created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, likely, look forward to, may, on track, plan, potential, predict, project, prospects, scheduled, should, slated, targeting, will, would and similar expressions and variations thereof. Forward-looking statements, including statements regarding anticipated regulatory submissions, expectations regarding regulatory exclusivities, the timing and results of ongoing or anticipated clinical trials, and the therapeutic application of Omeros investigational product, are based on managements beliefs and assumptions and on information available to management only as of the date of this press release. Omeros actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, availability and timing of data from clinical trials and the results of such trials, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading Risk Factors in the companys Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2019. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of any new information, future events or otherwise, except as required by applicable law.
Source: Omeros Corporation
- Pain treatment using human stem cells a success - News - The University of Sydney - January 24th, 2020
- PRP/Stem Cell Treatment Has Both Functional and Cosmetic Benefits - Haute Living - January 24th, 2020
- Daily briefing: First evidence of how stress turns hair grey - Nature.com - January 24th, 2020
- Gene Therapy for Sickle Cell Disease Receives Orphan Drug Designation - Monthly Prescribing Reference - January 24th, 2020
- High-Definition View of Diabetes-Related Proteins Obtained, Opening the Door to Future Treatments - SciTechDaily - January 24th, 2020
- Cynata Therapeutics to talk stem cell therapies at Proactive"s CEO Sessions - Proactive Investors Australia - January 24th, 2020
- Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of... - January 22nd, 2020
- Stem cell treatment off the table - Zululand Observer - January 22nd, 2020
- UK biotech PhoreMost to work with Otsuka on gene therapy projects - - pharmaphorum - January 22nd, 2020
- J&J wins another label expansion for Darzalex in Europe - PMLiVE - January 22nd, 2020
- Mayo woman raising funds for niece, 4, who is losing her sight from three different eye conditions - Extra.ie - January 22nd, 2020
- Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Predicted to Grow by 2028 with Competitive Situation and Business... - January 22nd, 2020
- Michael Schumacher health update: Neurosurgeon claims F1 legend 'nothing like we remember' - Express.co.uk - January 22nd, 2020
- Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position - GlobeNewswire - January 22nd, 2020
- Science Talk - Tell me more about telomeres: how 'basic' science can help us treat cancer - The Institute of Cancer Research - January 22nd, 2020
- The Clinical Trial that MS Patients Have Been Waiting For - Multiple Sclerosis News Today - January 19th, 2020
- Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News - Dagoretti News - January 19th, 2020
- Libby Clegg health: Dancing On Ice star is registered blind - what is her condition? - Express - January 19th, 2020
- Stem Cell Therapy Market is Anticipated to Attain a Market Value of US$XX by the End of 2017 2025 - Fusion Science Academy - January 19th, 2020
- Zika Virus' Key into Brain Cells ID'd, Leveraged to Block Infection and Kill Cancer Cells - UC San Diego Health - January 17th, 2020
- Koepka Tied for 3rd in Abu Dhabi in Return From Knee Injury - The New York Times - January 17th, 2020
- Giraffe Will Go Through Risky Procedure At Cheyenne Mountain Zoo To Treat Ongoing Health Issues - CBS Denver - January 17th, 2020
- Novel form of cell-free therapy revealed by researchers - Drug Target Review - January 17th, 2020
- Choosing the Best Therapy for Patients with Chronic Lymphocytic Leukemia - Curetoday.com - January 17th, 2020
- Astellas, Adaptimmune to develop CAR-T & TCR T-cell therapies - BSA bureau - January 17th, 2020
- Melton parents of seriously ill little girl appeal for help to treat her - Melton Times - January 17th, 2020
- Study: Mutations in stem cells of young donors can be passed to recipients - STAT - January 15th, 2020
- Landmark Results for CaverStem Procedure Published in Journal of Translational Medicine to Create Paradigm Shift in Treatment of Erectile Dysfunction... - January 15th, 2020
- Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related... - January 15th, 2020
- Bluebird Bio taps ex-Celgene exec Heffron to lead its first gene therapy launch - FiercePharma - January 15th, 2020
- Celgene exec jumps to head bluebird bio ops in Europe, where its $1.8M gene therapy Zynteglo is now available - Endpoints News - January 15th, 2020
- Hemogenyx's CAR-T Cells are Effective Against AML in vitro - GuruFocus.com - January 15th, 2020
- Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or... - January 15th, 2020
- How Exosomes Could Lead To Stroke Recovery - Technology Networks - January 15th, 2020
- Koepka Ready to Get Back to Work After Nearly 3 Months Off - The New York Times - January 14th, 2020
- Astellas teams with Adaptimmune to create CAR-T, TCR therapies - FierceBiotech - January 14th, 2020
- FROM THE LABS: There is a new player in adult bone healing - Baylor College of Medicine News - January 14th, 2020
- Global Stem Cell Market Is Projected to Grow at a CAGR of 11.9% During the Forecast Period - Press Release - Digital Journal - January 14th, 2020
- Allogeneic Stem Cells Market Expected to Grow with a CAGR of 12% Due to New Product Approvals, 2020-2024 - ResearchAndMarkets.com - Business Wire - January 14th, 2020
- Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers -... - January 14th, 2020
- Stem cell agency indirectly boosted by national industry group - Capitol Weekly - January 13th, 2020
- Muscular dystrophy collaboration aims to correct muscle stem cells' DNA - Harvard Office of Technology Development - January 13th, 2020
- AstroRx Increased Ability to Perform Daily Functions in ALS Patients - ALS News Today - January 13th, 2020
- Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood - Yahoo Finance - January 13th, 2020
- Police Arrest 3 in Illegal Stem Cell Therapy Allegations - Tempo.co English - January 13th, 2020
- Stem Cell Therapy Market Competitive Analysis 2019-2027 - News ZMR - January 13th, 2020
- Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer | More News | News... - January 13th, 2020
- First ever progressive MS treatment approved for use by NHS in Scotland - The Scotsman - January 13th, 2020
- Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers - Yahoo... - January 13th, 2020
- The potential use of CRISPR to treat disease is gaining momentum - BioNews - January 13th, 2020
- At 16, Shes a Pioneer in the Fight to Cure Sickle Cell Disease - The New York Times - January 12th, 2020
- At 16, shes a pioneer in the fight to cure sickle cell disease at Boston Childrens - Boston.com - January 12th, 2020
- What is Mantle Cell Lymphoma and How Is It Treated? - Dana-Farber Cancer Institute - January 12th, 2020
- Doug Richards remembered - faribaultcountyregister.com | News, Sports, Information on the Blue Earth region - Faribault County Register - January 12th, 2020
- Kadimastem Finishes Treating Second Group of ALS Patients with AstroRx in Phase 1/2a Trial - ALS News Today - January 11th, 2020
- Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million - Business Wire - January 11th, 2020
- Global Stem Cell Therapies Overview Report 2019: The Highs & Lows, Off-The-Shelf Solutions, New Technologies, and Safety, Efficacy & Logistical... - January 11th, 2020
- Q&A: Cancer Death Rates Are Falling Nationally. Here's What's Happening at UVA - University of Virginia - January 11th, 2020
- SVC112 molecule reduces effects of cancer stem cells with little toxicity - Drug Target Review - January 11th, 2020
- Helius Medical Technologies Awarded Pioneer Technology Development AwardBrain Mapping Foundation and Society for Brain Mapping Therapeutics name the... - January 11th, 2020
- ANP Technologies, in Partnership with Fulgent Pharma, Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies - Business Wire - January 11th, 2020
- Orgenesis adds UC Davis to its point-of-care network for developing cell, gene therapy products - Proactive Investors USA & Canada - January 11th, 2020
- Barry reveals the truth about Fiona on Fair City - RTE.ie - January 11th, 2020
- What will be the biggest scientific breakthrough of 2020? - Stuff.co.nz - January 11th, 2020
- Global Stem Cell Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025 - BulletintheNews - January 11th, 2020
- Promethera Announces Initiation of Phase 2b DHELIVER Study of HepaStem in Patients with Acute-on-Chronic Liver Failure (ACLF) - Business Wire - January 9th, 2020
- Avacta and Daewoong Pharmaceutical Form Immunotherapy Focused Joint Venture - Technology Networks - January 9th, 2020
- Global Stem Cell Therapy Market Size is anticipated to grow at a strong CAGR by 2025 - Technology Magazine - January 9th, 2020
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - ReportsPioneer - January 9th, 2020
- Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as... - January 9th, 2020
- CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis - Associated Press - January 9th, 2020
- Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - Yahoo... - January 9th, 2020
- Kevin Nash on How His Health Is After Knee Replacement & Stem Cell Therapy, Why He Retired - LordsofPain.net - January 9th, 2020
- Stem Cell Alopecia Treatment Market 2019 Globally Expected to Drive Growth through 2024 - ReportsPioneer - January 9th, 2020
- Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference - GlobeNewswire - January 9th, 2020
- Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - BioSpace - January 7th, 2020
- Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR Therapy for Relapsed or Refractory T-cell Malignancies - PRNewswire - January 7th, 2020
- Patrick Reed's latest controversy and the other things in golf that matter right now - ESPN - January 7th, 2020
- Diomics Corporation and University of California, Irvine Collaborate to Enable Cell Therapy Clinical Trial for Type 1 Diabetes - GlobeNewswire - January 7th, 2020
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Explores The Key Success Factors, And Business Opportunities Including Key... - January 7th, 2020